Related Experiment Video

Updated: Jun 8, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene

Nadia Harbeck1, Mark D Pegram, Josef Rüschoff

  • 1Brustzentrum Köln/Frechen, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe der Uniklinik Köln, Germany.

Breast Care (Basel, Switzerland)
|September 18, 2010
PubMed

Insights

Immunotherapy is vital for metastatic breast cancer. While trastuzumab targets HER2/ErbB2, resistance necessitates new anti-ErbB2 strategies for improved patient outcomes.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Targeted Therapy

Background:

  • Immunotherapy is a key treatment for metastatic breast cancer, alongside traditional therapies.
  • The HER2/ErbB2 receptor is a significant target, overexpressed in 20-25% of breast cancers.
  • Accurate HER2/ErbB2 status determination is crucial due to the poor prognosis associated with high expression levels.

Purpose of the Study:

  • To review the role of immunotherapy in metastatic breast cancer.
  • To discuss the efficacy and limitations of HER2/ErbB2-targeting therapies like trastuzumab.
  • To highlight the need for novel anti-ErbB2 strategies due to acquired resistance.

Main Methods:

  • Review of clinical trial data on immunotherapy and HER2/ErbB2-targeted agents.
  • Analysis of resistance mechanisms to current therapies.
  • Synthesis of evidence supporting the development of alternative treatment strategies.

Main Results:

  • Trastuzumab, an approved HER2/ErbB2-targeting therapy, shows initial efficacy in ErbB2-positive breast cancer.
  • A significant proportion of patients develop resistance to trastuzumab-based regimens within one year.
  • The need for alternative or supplementary anti-ErbB2 strategies is clearly indicated.

Conclusions:

  • Immunotherapy is an established treatment for metastatic breast cancer.
  • Despite trastuzumab's approval, acquired resistance limits its long-term effectiveness.
  • Further research into novel anti-ErbB2 therapies is essential for overcoming treatment resistance.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...